Myriad Genetics
Market Cap
US$912.5m
Last Updated
2020/04/04 23:37 UTC
Data Sources
Company Financials +
Executive Summary
Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests worldwide.
Rewards
Risk Analysis
Snowflake Analysis
Mediocre balance sheet and slightly overvalued.
Similar Companies
Share Price & News
How has Myriad Genetics's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MYGN's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-12.9%
MYGN
2.0%
US Biotechs
-2.8%
US Market
1 Year Return
-62.7%
MYGN
-1.3%
US Biotechs
-15.9%
US Market
Return vs Industry: MYGN underperformed the US Biotechs industry which returned -0.9% over the past year.
Return vs Market: MYGN underperformed the US Market which returned -15.1% over the past year.
Shareholder returns
| MYGN | Industry | Market | |
|---|---|---|---|
| 7 Day | -12.9% | 2.0% | -2.8% |
| 30 Day | -29.1% | -8.0% | -18.8% |
| 90 Day | -54.4% | -4.6% | -24.0% |
| 1 Year | -62.7%-62.7% | -0.5%-1.3% | -14.2%-15.9% |
| 3 Year | -34.5%-34.5% | 13.3%10.5% | 9.9%2.8% |
| 5 Year | -65.5%-65.5% | -7.7%-12.0% | 27.2%13.3% |
Price Volatility Vs. Market
How volatile is Myriad Genetics's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall St
One Thing To Remember About The Myriad Genetics, Inc. (NASDAQ:MYGN) Share Price4 weeks ago | Simply Wall St
Myriad Genetics (NASDAQ:MYGN) Is Making Moderate Use Of Debt1 month ago | Simply Wall St
Don't Ignore The Fact That This Insider Just Sold Some Shares In Myriad Genetics, Inc. (NASDAQ:MYGN)Valuation
Is Myriad Genetics undervalued compared to its fair value and its price relative to the market?
16.6%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: MYGN ($12.24) is trading below our estimate of fair value ($14.68)
Significantly Below Fair Value: MYGN is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: MYGN is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: MYGN is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MYGN's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MYGN is good value based on its PB Ratio (0.8x) compared to the US Biotechs industry average (2.5x).
Next Steps
Future Growth
How is Myriad Genetics forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?
13.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MYGN is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MYGN is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MYGN is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MYGN's revenue (2.4% per year) is forecast to grow slower than the US market (7.1% per year).
High Growth Revenue: MYGN's revenue (2.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MYGN's Return on Equity is forecast to be low in 3 years time (5.1%).
Next Steps
Past Performance
How has Myriad Genetics performed over the past 5 years?
-27.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MYGN is currently unprofitable.
Growing Profit Margin: MYGN is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MYGN is unprofitable, and losses have increased over the past 5 years at a rate of -27.3% per year.
Accelerating Growth: Unable to compare MYGN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MYGN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (22%).
Return on Equity
High ROE: MYGN has a negative Return on Equity (-2.44%), as it is currently unprofitable.
Next Steps
Financial Health
How is Myriad Genetics's financial position?
Financial Position Analysis
Short Term Liabilities: MYGN's short term assets ($365.3M) exceed its short term liabilities ($112.4M).
Long Term Liabilities: MYGN's short term assets ($365.3M) do not cover its long term liabilities ($388.6M).
Debt to Equity History and Analysis
Debt Level: MYGN's debt to equity ratio (20.9%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if MYGN's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Inventory Level: MYGN has a low level of unsold assets or inventory.
Debt Coverage by Assets: MYGN's debt is covered by short term assets (assets are 1.6x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MYGN has been profitable on average in the past, therefore cash runway is not a concern.
Forecast Cash Runway: MYGN has been profitable on average in the past, therefore cash runway is not a concern.
Next Steps
Dividend
What is Myriad Genetics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MYGN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate MYGN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MYGN's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MYGN's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MYGN's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.3yrs
Average management tenure
CEO
R. Riggsbee (48yo)
0.17
Tenure
US$3,138,983
Compensation
Mr. R. Bryan Riggsbee serves as an Interim President & Chief Executive Officer of Myriad Genetics, Inc. since February 6, 2020. He had been the Chief Financial Officer and Treasurer of Myriad Genetics Inc. ...
CEO Compensation Analysis
Compensation vs Market: R.'s total compensation ($USD3.14M) is about average for companies of similar size in the US market ($USD3.31M).
Compensation vs Earnings: R.'s compensation has increased whilst the company is unprofitable.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Interim President | 0.17yr | US$3.14m | 0.085% $778.2k | |
| Chief Operating Officer | 0.25yr | US$3.23m | 0.083% $756.5k | |
| Chief Scientific Officer | 10.17yrs | US$2.69m | 0.16% $1.4m | |
| Vice President of Investor Relations | no data | no data | no data | |
| Executive VP | 0.75yr | no data | 0.075% $685.4k | |
| Chief Compliance Officer | 1.25yrs | no data | no data | |
| Executive Vice President of Corporate Communications | no data | no data | no data | |
| Executive Vice President of Human Resources | 8.92yrs | no data | no data | |
| Executive Vice President of International Operations | 9.75yrs | no data | 0.11% $962.7k | |
| President of Myriad Autoimmune | 5.25yrs | US$2.73m | 0.093% $849.3k |
3.3yrs
Average Tenure
54.5yo
Average Age
Experienced Management: MYGN's management team is considered experienced (3.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Independent Director | 10.58yrs | US$380.49k | 0.066% $601.1k | |
| Independent Vice Chairman | no data | US$369.99k | 0.057% $519.8k | |
| Independent Director | 15.92yrs | US$482.49k | 0.089% $812.8k | |
| Independent Director | 15.92yrs | US$392.49k | 0.050% $458.0k | |
| Independent Director | 0.58yr | no data | no data | |
| Independent Director | 0.58yr | no data | no data | |
| Independent Director | 9.83yrs | US$384.99k | 0.058% $527.6k | |
| Independent Chair of the Board | 0.083yr | US$399.49k | 0.045% $409.0k |
9.8yrs
Average Tenure
66.5yo
Average Age
Experienced Board: MYGN's board of directors are considered experienced (9.8 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: MYGN insiders have only sold shares in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.8%.
Top Shareholders
Company Information
Myriad Genetics, Inc.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Myriad Genetics, Inc.
- Ticker: MYGN
- Exchange: NasdaqGS
- Founded: 1991
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$912.493m
- Shares outstanding: 74.55m
- Website: https://myriad.com
Number of Employees
Location
- Myriad Genetics, Inc.
- 320 Wakara Way
- Salt Lake City
- Utah
- 84108
- United States
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| MYGN | NasdaqGS (Nasdaq Global Select) | Yes | Common Stock | US | USD | Oct 1995 |
| MYD | DB (Deutsche Boerse AG) | Yes | Common Stock | DE | EUR | Oct 1995 |
| MYD | XTRA (XETRA Trading Platform) | Yes | Common Stock | DE | EUR | Oct 1995 |
| 0K3W | LSE (London Stock Exchange) | Yes | Common Stock | GB | USD | Oct 1995 |
Biography
Myriad Genetics, Inc., a molecular diagnostic company, develops and markets predictive, personalized, and prognostic medicine tests worldwide. The company offers myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; and riskScore, a personalized medicine tool. It also provides BRACAnalysis CDx, a DNA sequencing test for use in identifying ovarian and HER2 negative metastatic breast cancer patients with deleterious or suspected deleterious germline; GeneSight, a DNA genotyping test to aid psychotropic drug selection for depressed patients; and Vectra, a protein quantification test for assessing the disease activity of rheumatoid arthritis. In addition, the company offers Foresight, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; Prequel, a non-invasive prenatal screening test to screen for severe chromosomal disorders in a fetus; and Prolaris, a RNA expression test for assessing the aggressiveness of prostate cancer. Further, it provides EndoPredict, a RNA expression test for assessing the aggressiveness of breast cancer; myPath Melanoma, a RNA expression test for diagnosing melanoma; and myChoice HRD, a companion diagnostic to measure three modes of homologous recombination deficiency comprising loss of heterozygosity, telomeric allelic imbalance, and large-scale state transitions in cancer cells. Additionally, the company offers biomarker discovery, and pharmaceutical and clinical services to the pharmaceutical, biotechnology, and medical research industries; and operates an internal medicine emergency hospital primarily for internal medicine and hemodialysis. The company has collaboration with AstraZeneca for the development of an indication for BRACAnalysis CDx. Myriad Genetics, Inc. was founded in 1991 and is headquartered in Salt Lake City, Utah.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/04/04 23:37 |
| End of Day Share Price | 2020/04/03 00:00 |
| Earnings | 2019/12/31 |
| Annual Earnings | 2019/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.